Acne

NDA submitted to FDA for acne product

Published in Biotech Business Week, September 27th, 2004

Atrix Laboratories, Inc., (ATRX) announced that on August 31, 2004, together with co-development partner Fujisawa Healthcare, Inc., they submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Aczone Gel 5%(dapsone topical gel), formerly called Atrisone, for the treatment of acne vulgaris.

"We are excited about the submission of this NDA for Aczone," said David R. Bethune, Atrix's chairman and chief executive officer.

"We are proud of the extraordinary hard work, commitment, and dedication of the Aczone development team, made up of representatives from both Atrix and Fujisawa. The submission of this NDA illustrates...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-09-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry